Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Fibromyalgia

In brief

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2 parts. Part A enrolled 211 pts dosed with either 3, 20, 60 mg BID AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 440 pts and dose with either 20, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.

Key facts

Study ID

NCT00445705

Run by

Allergan

People needed

211

Starts

2007-03-01

Expected to finish

2008-01-01

Last updated by the study team

2015-09-07

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of fibromyalgia syndrome
• Moderate or severe pain associated with fibromyalgia

You may not qualify if…

• Any other uncontrolled disease
• Pregnant or nursing females

Where it is running

• Study site — Canton, Ohio, United States
• Study site — Geneva, Switzerland
• Study site — Stanmore, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.